Clinical trial
A Single-arm, Open-label Exploratory Clinical Study to Assess the Preliminary Safety of the Gene Editing Drug ZVS203e for the Management of Retinitis Pigmentosa Caused by Mutations in the RHO Gene
NCT05805007 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm, Open-label Exploratory Clinical Study to Assess the Preliminary Safety of the Gene Editing Drug ZVS203e for the Management of Retinitis Pigmentosa Caused by Mutations in the RHO Gene
- Lead sponsor
- Peking University Third Hospital
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- September 12, 2023
- Completion date
- April 30, 2026
- Enrollment
- 9 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.